At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,655 enrolled
Drug / intervention
Alteplasedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safe Implementation of Treatments in Stroke (SITS) - Intravenous Thrombolysis in Acute Ischaemic Stroke Patients Over 80 Years, SITS-IVT>80 Years Study
In Brief
An observational study evaluating Alteplase for Ischaemic Stroke. Completed, enrolled 1,655 participants across 1 site.
Detailed Summary
A non-interventional post-approval study on Safe Implementation of Treatment in Stroke - International Stroke Thrombolysis Register (SITS-ISTR) existing data of intravenous recombinant tissue plasminogen Activator (rt-PA) (0.9 mg/kg) in acute ischaemic stroke patients over 80 years, treated according to the Summary of Product Characteristics (SmPC) in European countries.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIschaemic Stroke
CountriesSweden
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartMay 2020
Primary CompletionDec 2022
TodayJul 2026
First PostedFeb 7, 2020
Enrollment StartMay 14, 2020
Primary CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.4 years ago
Interventions
Alteplasedrug
Intravenous injection